Life Sciences Archive » May, 2022

Life Sciences - May, 2022

314 articles

• FCA Split Has High Court Momentum Despite DOJ's Critique
• Ex-CEO Facing Indictment, SEC Suit Over COVID-19 Test Kits
• 11th Circ. Won't Revive Medical Co.'s Coverage Suit
• Regeneron Rips Amgen's 'Bundling Scheme' Amid IP Feud
• Skinny Labels' Future May Hinge On Teva Petitioning Justices
• 2 FCA Settlements Highlight Gov't Cyber Liability Focus
• CRISPR Nobel Prize Winners Beat European Patent Challenge
• Catching Up With Delaware's Chancery Court
• 2 Firms Guide Cardio Diagnostics' $175M SPAC Merger
• Iowa Justices Affirm Possession Conviction For Pot Patient
• Cannabis Moneyball Has Begun, And The Game Is Heating Up
• Law360 Names 2022's Top Attorneys Under 40
• Opioid Judge Raiding Settlements For Atty Fees, 6th Circ. Told
• Texas High Court To Weigh In On Cotton Crop Pesticide Fight
• USTR Again Extends China Tariff Reprieve For COVID-19 Gear
• Cannabis Bill Roundup: New Legalization Proposal In NC
• Janssen Launches Patent Suit Over Prostate Cancer Drug
• Justices Should Give Feds' Roundup Amicus Little Weight
• Biopharma Co.'s Lies Caused Investor Losses, Suit Claims
• FDA Sends Warning Letters To Cos. Selling CBD Animal Drugs
• Hirshfeld's Arthrex Clearance Empowers Interim Leaders
• Teva And Cephalon's Marketing Ignored Plea Deal, Judge Told
• Ex-Theranos Exec's Fraud Trial Delayed Until June 7
• Drink Co. Touted Health Claims To Skirt Calif. Fees, Jury Told
• J&J Aims To Block Counsel Deposition In Ex-Exec's Bias Suit
• Cardinal Investors Reach $124M Settlement In Opioid Suit
• 11th Circ. Won't Revive Optometry Clinic's Virus Coverage Suit
• No Toss For Del. Suit Targeting $11.6B Sanofi-Bioverativ Deal
• Startup Wants Illumina Trade Secret Suit Tossed
• ABA Isn't Giving Up On Diversity Efforts By Ending CLE Rule
• 3rd Circ. Won't Undo Investors' Win Over 'True Fraudster'
• J&J Unit Hit With BIPA Suit Over Skin Care App's Face Scans
• Nuclear Med JV Looks To Keep Award Enforcement In NY
• 'Profound' Stakes In Drug Discount Suit, Eli Lilly Tells 7th Circ.
• PTAB Ruling Shows Need To Split Terminal Disclaimer
• Pharmacy Owner Gets 4 Years For $7.2M Rebate Fraud
• Sens. Urge FDA, USPTO To Cooperate On Generic Drugs
• Monsanto Knew Of PCBs' Dangers, Jury Hears In Latest Trial
• Walmart Can't Escape Suit Over Crash That Killed Girl Scouts
• Generic Distributors Slip Indirect Reseller Price-Fixing Claims
• Arnold & Porter Stuck In Sanctions Scuffle Despite Endo's Exit
• SF Opioid Judge Is Told Cos. Put Profits First In Marketing
• Witness Travel 'Not My Problem,' Judge Tells Drink Co. Attys
• How To Protect Health Care Trade Secrets With Covenants
• Feds Tell Justices Not To Wade Into Anthem Drug Price Case
• FDA Found 'Egregious' Conditions At Abbott Baby Food Plant
• Lateral Candidate Screening Steps To Prevent Bad Behavior
• Using Bayh-Dole For Cancer Drug March-In Rights Is Wrong
• Nipro Corp. Pays $21M After Avoiding ICC Arbitration Award
• Pfizer To Sell Low-Cost COVID Vaccine, Drugs To Poor Nations
• Pharma Co. Data Breach Exposed 75K Patients' Info, Suit Says
• Atty Wants SEC Penalties Delayed Amid Jury Polling Kerfuffle
• Del. Justices Take 'Critical' Look At Zimmer Biomet Suit
• Masimo Says Stay Is Over In Apple Patent Fight
• Teva, Allergan Strike $161M Deal With W.Va. AG In Opioid Case
• FCA Pleading Split Is Finally Kaput, DOJ Tells High Court
• Ex-Anda Chief OK'd Unlimited Opioid Supplies, Judge Hears
• FTC Launches Inquiry Into Infant Formula Shortage
• Fed. Circ. Told PTAB Flouted AIA In Gene-Editing Interference
• Investors' Attys Seek $29M Cut Of Novo Nordisk Deal
• CSL Plasma Inks $9.9M BIPA Deal With Blood Plasma Donors
• Pay Consultant Traded On Client's Sanofi Intel, Feds Say
• Justices Urged Not To Review $87M Monsanto Roundup Loss
• HSR Statistics Show Increasing Scrutiny Of Health Care M&A
• Committee Pros Approved In J&J Talc Unit's Ch. 11 Case
• A Look At The Legal Profession Since Murder Of George Floyd
• Fed. Circ. Won't Breathe New Life In Cornell's Enzyme Patent
• Week In Bankruptcy: Dioceses Settle; Wind-Downs Reined In?
• Mylan Hit With Infringement Suit Over MS Generic Drug
• Fed. Circ. Acne Drug IP Holding Clarifies Obviousness Factors
• 2 Firms Will Lead Northwest Biotherapeutics Pay Suit In Del.
• Joint Juice Is 'Snake Oil,' Not Health Aid, Jurors Hear
• Moderna Wants Claims In COVID-19 Vax Patent Suit Tossed
• DEA Draws Judge's Ire In Calif. Opioid Trial
• Judge Skeptically Probes Fate Of FDA's Cigar Regulation
• Ethicon Loses Fed. Circ. Bid To Revive Surgical Tool Patent
• Novartis Owes Royalties, Bristol-Myers Squibb Says
• Mallinckrodt Calls Shareholder Ch. 11 Stay Bid Untimely
• Vanda Fights FDA's Refusal To Fast-Track Gastro Drug Review
• Monsanto Urges High Court To Take Up $25M Roundup Verdict
• NY Ruling Correctly Deems Legal Finance Docs Irrelevant
• Addressing Low Response Rates In Expert Surveys
• Avanir Hit With Suit Over Alleged Nuedexta Kickback Scheme
• McCarter & English Enters Midwest With New Indiana Office
• Catching Up With Delaware's Chancery Court
• Balwani Trial Goes On, Despite Juror's Positive COVID-19 Test
• Ex-Claims Court Chief Chides Warren's Drug Pricing Plan
• FDA Won't Totally Ban Phthalates From Food Packaging
• Gilead Loses Patent Case Over Lexiscan Generic
• First Wave Bio Investors Sue In Del. For AzurRx Merger Money
• Fed. Circ. Says Child Due Compensation For Vaccine Injuries
• Ill. BCBS Hit With Fertility Treatment Bias Claims
• Chancery Warns EpicentRx About 'Flouted' Case Deadlines
• Drugmakers Say Pa. AG Not Producing Generic-Drug Docs
• Health Hires: Pharvaris, VistaGen, Dykema
• New Suit Targets FAA's OK Of Ga. Rocket Launch Site
• Holmes' Sealed Docs Might Sway Balwani Jury, Judge Says
• 7th Circ. Tore 'Gaping Hole' In FCA, Grassley Tells High Court
• SF Fire Dept. Treats 7 Opioid Overdoses Daily, Judge Told
• Del. Judge Dumps Suit Targeting DuPont Spinoff's Enviro Bills
• Ill. Court Reverses J&J Contempt In Talc Cancer Case
• IP Forecast: Crocs Takes Look-Alike Shoe Fight To ITC
• FDA Defeats Ban On Warning Of Veterinary Pharmacy's Drugs
• Epstein Becker Taps Wilentz Cannabis, Health Care Pro
• Fed. Circ. Upholds PTAB Ax Of J&J Unit's Surgical Patent
• Justices Told Fraud Tainted Vascepa Patent Invalidations
• Valisure Can't Get Fees For Quashed Subpoena In Zantac MDL
• 3rd Circ. Won't Revive Federal Claim On Pharma Accreditation
• WTO Talks On Vaccine Patents Falter As Pandemic Surges
• Procopio Adds Life Sciences IP Attorney From Snell & Wilmer
• 11th Circ. Ban On Service Awards May Inhibit Class Actions
• Overcommunicate With Your Summer Associates This Year
• ERISA Ruling Shows Lax Enrollment Practices Can Be Costly
• Medtronic Worker Can't Escape $1.3M Claim In Poaching Suit
• Even With Pandemic, Patent Suit Filings Held Steady In 2021
• 7th Circ. Throws Out $11M Fee Award For Bernstein Litowitz
• Balwani Shut Down $96M Investor's Due Diligence, Jury Told
• Many SF Walgreens Opioid Scripts Had Red Flags, Judge Told
• Hemp Biz Group Urges FDA Action On CBD After New Study
• AbbVie Execs Put 'Profits Over Compliance,' Investor Says
• 'Pharma Bro' Shkreli Released From Federal Prison Early
• IQVIA Holds On To Key Defense In Trade Secrets Spat
• Mallinckrodt Noteholders Say They're Owed $94M For Default
• The State Of Intradistrict Venue Transfer In West Texas
• Judge Invalidates Medicaid 'Accumulator Adjustment Rule'
• Purdue Ch. 11 Bonus Plan Gets Court OK, CEO's Delayed
• Medical Device Co. Sues Unit Founder For Starting Competitor
• Docs Urge 1st Circ. To Revive J&J Hip Replacement FCA Suit
• Novartis' DQ Bid Sinks In Gilenya Row
• What FDA Warning Letters Signal About Delta-8 Enforcement
• Biotech Research Center Escapes Engineer's Paid Leave Suit
• Nev. Case Highlights Settlement Authority Dilemmas For Cos.
• Teva Unit Marketed Opioid For Off-Label Uses, Judge Hears
• Ohio Counties Put On Show In Opioid Damages Trial
• The Week In Bankruptcy: Purdue Bonus, PR Pension Appeal
• Neb. Medical Pot Campaign Sues Over 'Unconstitutional' Rule
• FDA Clears COVID-19 Boosters For 5-11 Age Group
• Vaping Cos. Say FDA Changed Rules On Flavored Products
• Hospitals Rally Around Drug Discounts In Pharma Fight
• USPTO Asks Fed. Circ. Not To Rule On Hirshfeld's Power
• Sick Juror Delays Ex-Theranos Exec's Criminal Fraud Trial
• Key Rulings And Cases As COVID Claimed 1M American Lives
• Atty Asks New Judge For SEC Trial Redo After Polling Blunder
• Bristows Boosts Life Sciences Team With Partner Promotion
• Yale New Haven Health Atty Joins Dana-Farber As GC
• Judge Says Cos. Don't Have To Cover Gender Transition Care
• FCA Intrigue Intensifies As High Court Again Invites DOJ Input
• Doctors' Opioid Data Kept From Walgreens Stores, Judge Told
• Counties Bungled $875M Ask After Opioid Trial, Judge Told
• Hemp Equipment Seller's Counterclaims Fail, Court Told
• Gilstrap Won't Pause $42M Seagen Drug Patent Row For PTAB
• Finding Uninjured Consumers In Drug Antitrust Class Actions
• High Court Won't Hear 3M's Appeal In Surgical Blanket Case
• Catching Up With Delaware's Chancery Court
• Medical Testing Co. Sues For More Time To Pay $4M Loan
• Pharma Products' Uncertain Path To Patient Assistance
• Insys Founder Says Looming Opioid Ruling Boosts Appeal
• Walgreens Deal Spurred Quick Theranos Investment, Jury Told
• Pharmaceutical Co. Sued Over Recalled Thyroid Medication
• Ex-Lab Exec Wants FCA Suit Axed Over 'Blood Money' Book
• States Say Purdue CEO Should Answer For Opioid Crisis Role
• Drugmaker Wants $950M Vaccine Trade Secrets Suit Tossed
• Texas v. Pandemic: How The Lone Star State Litigated COVID
• 2 Approaches To NY Choice Of Law In Employment Contracts
• Ohio Pharmacy Board Subpoena Case Returned To Trial Court
• The Fastest Federal Trial Courts: A Look At Virginia, Florida
• Womble Bond Expands IP Practice In Texas, NC
• Consulting Firm Wants Out Of Ark. Pot Licensing Suit
• 'Measly' Opioid Fine Invites BigLaw Defiance, NY AG Warns
• Walgreens' Priority Was Filling Drug Orders Fast, Judge Told
• Air Force Wants To Toss Vax Mandate Challenge
• ABA Calls For Better Security For High Court, Federal Bench
• IP Forecast: 9th Circ. To Hear A Tale Of Two Punchbowls
• 3 Takeaways As China Rolls Out Its Version Of ANDA Disputes
• Cannabis Co. Nabs Atty Fees In CBD Cream Patent Row
• 9th Circ. Hunts For Rationale To Cut $925M ViSalus TCPA Loss
• Auctioneer Says Cancer Charity To Blame For Embezzlement
• French SPAC Raises $156M To Support Drug Development
• Fed. Circ. Says LabCorp Missed Chance To Move Patent Row
• TGIF: Why Juries Love To Start The Weekend With A Verdict
• Synthetic Nicotine Industry Could Be Set To Evaporate
• Bid Protest Spotlight: Late-Is-Late, Party Interest, Timeliness
• Pension Fund Asks 11th Circ. To Revive Suit Against MiMedx
• Tips For Evaluating Machine Learning For Contracts Review
• Conspiracy Caused Insulin Price Spike, Arkansas Says
• Walgreens' Opioid Orders Like A 'Time Bomb,' Judge Told
• W.Va. Opioid Defense Expert Testifies Death Data Are Suspect
• Settlements Worth $86M OK'd In Drug Price-Fixing MDL
• DOJ Ups Marshal Security For Justices Amid Roe Protests
• Balwani Invoked Lawyers To Cow Wavering Investor, Jury Told
• Ex-Sleep Number Execs Can't File For Patents, 8th Circ. Says
• Fla. Court Erases $148M Punitive Damages In Smoker's Suit
• Lawmakers Say Emergent Destroyed 400M COVID Vaccines
• How Russia's Parallel Import Order May Affect Companies' IP
• Feds Settle GMO Salmon Suit Fees Issue With Enviro Groups
• SEC Slams Priest For 'Galling' New Fraud Trial Bid
• J&J Ch. 11 Talc Claimants Get Nod For 3rd Circ. Appeal
• Senate Vote To Codify Roe Abortion Protections Fails
• Why Cos. Are Betting On Cannabis Drinks Despite Legal Risks
• FDA Asks To Nix Ban On Warning Of Animal Pharmacy's Drugs
• Counsel Leadership Fight Heats Up In Pharma Pay Suit In Del.
• Doctor Who Gave Out 'Goodie Bags' Of Drugs Gets 20 Years
• Conn. Atty Says SEC Lacked Evidence For Fraud Trial Win
• Chancery Orders Biogen To Give Documents To Investor
• Opioid Jurors Detail Talks As Pharmacy Trial Gets Feisty Start
• 'Catastrophic' SF Opioid Death Toll Like AIDS Era, Judge Told
• End-Payor State Claims Stick In Generic Drug Price-Fix MDL
• Balwani Didn't Void Tests After Feds Flagged Issues, Jury Told
• Ex-Pharma CFO Indicted For Allegedly Giving Girlfriend Info
• Medtronic Shedding Intersect Unit For $1B Deal
• Full 4th Circ. To Eye $680M FCA Case Against Allergan
• Feds Ask Justices To Let $25M Monsanto Roundup Verdict Be
• Judge Vacates Pot Co. Investors' Class Certification, For Now
• Attys Urge 4th Circ. To Revisit W.Va. Law On Drug Case Ads
• Animal Health Co. Investors Nab $35M Deal Over Spinoff
• Sanitizer Co. Gets OK For Ch. 11 Loan To Destroy Products
• DC Circ. Revives Plasma Companies' Visa Policy Suit
• Gilead Slaps Rivals With Patent Suit Over HIV Drug
• Sens. Rip Biden Admin. For Cutting Them Out Of Trade Policy
• How To Efficiently Deploy Your Professional Growth Strategy
• Researchers Want DEA To Move On Pot Import Application
• Pfizer To Buy Biohaven Pharmaceuticals In $11.6B Deal
• Massive Opioid Campaign Duped Docs, Bellwether Judge Told
• 'No Legitimate Basis' For New Opioid Trial, NY AG Insists
• Surgeon Wants Patent Win Against J&J Unit Tripled To $60M
• Judge OKs $75M Deals In Contact Lens Price-Fixing Suit
• Biopharmaceutical Co. Investor Contests Director Pay In Del.
• 8th Circ. Says Insurer Flouted ERISA In Paperwork Mishap
• A 6-Step Framework For Legal Industry Professional Growth
• ITC Recommends Exclusion Order In Case Warning Of IP Theft
• Fed. Circ. Won't Block Generic Lung Drug During Appeal
• Catching Up With Delaware's Chancery Court
• Chancery Should Order Biogen To Give Up Docs, Report Says
• Seller Of Racehorse PEDs In 2020 Doping Scandal Convicted
• Why Contempt May Be Apt Punishment For High Court Leaker
• Moderna Says COVID-19 Vax Patent Suit Should Be Tossed
• Pharmacies Face Key Trial Test As Opioid MDL Intrigue Swirls
• Fed. Circ. Mulls Scope Of Eye Tech Software Injunction
• Walgreens Says Insurers Must Defend It In Opioid Cases
• Judge Ruled On Investors' Class Cert. Too Early, Pot Co. Says
• Fed. Circ. Rejects Narcan Maker's Redo Bid In Patent Suit
• After $12M Jury Win, Israeli Biz Asks Albright To Triple That
• Chancery Dismisses Suit Against Ex-Medical Pot Pharma Co.
• Judge Axes Benicar Fee Suit, Says Firm Didn't Overcharge
• Illumina Told To Pay $334M In DNA Sequencing Patent Trial
• Without Dissents, Dobbs Draft Is One-Sided Abortion Debate
• Veterinary Pharmacy Sues FDA To Block Products Warning
• Anthem Gets Spinal Device Coverage Denial Suit Tossed
• 5 Firms Steer Bausch & Lomb's Below-Range $630M IPO
• WilmerHale Brings In Gibson Dunn Technology Litigator In SF
• FDA Significantly Curtails J&J's COVID Vaccine Clearance
• 5 Law Firms Guide Centene's $2.8B Pharmacy Divestments
• IP Updates: E-Filing Grows In US; Payments OK'd For Russia
• Novartis Can't DQ Rival's Atty In Drug IP Row, Report Says
• Investors In Pot Co. Aphria Win Class Cert. In $144M Suit
• Fed. Circ. Partly Revives Another Surgical Robot IP Challenge
• Biotech Co.'s Ex-CEO Delayed In Suing Board, Court Says
• Mass. Woman Can't Revive Genzyme Injection Injury Suit
• Eligibility Law Keeps Evolving As American Axle Awaits SG
• Psychedelic Sector Can Learn From Cannabis Legal Hurdles
• Spinal Device Co. Inks $1M Midtrial Deal To End FCA Claims
• UMass Student's Graduation May End Vax Suit, 1st Circ. Hints
• Clients' Diversity Mandates For Law Firms Are Necessary
• Florida And Walgreens End Opioid Trial With $683M Deal
• J&J Says Benefit Co. Bilked Millions From Patient Drug Fund
• Balwani Can't Use Giant Spreadsheet In Theranos Defense
• Spinal Implant Co. Accused Of Doctor Kickbacks In FCA Trial
• House Lawmakers Unveil FDA Spending Package
• Chancery OKs $2.3M Deal To End Cancer Drug Disclosure Suit
• Expanded Talc Claim Committee Nixed In J&J Unit's Ch. 11
• Ex-Dean Gets 1 Year For Defrauding $651K From Student Org.
• Hemp Industry Eyes Major Changes In Next Farm Bill
• FDA Warns Cos. They're Illegally Marketing Delta-8 THC Goods
• Harvard, 10x Say Rival Co. Infringed Spatial Imaging Patents
• Del. Chancery Stays Stimwave Tech's Battle With Ex-CEO
• Even If Roe Is Dead, Abortion Suits Are Far From Over
• Chemical Co. Told To Provide Docs In Patent Row With Ecolab
• Policyholder Gains In Virus Coverage State Trial Court Suits
• Air Force Members Want Class Cert. In Ga. Vax Mandate Case
• Full Fed. Circ. Won't Eye New PTAB Forum Selection Ruling
• Pfizer Scientist Didn't OK Theranos Using Logo, Jury Hears
• Clues In Alito's Draft Suggest He's Not Reaching For Roberts
• Alito's Leaked Opinion May Be Far From Final Word On Roe
• Leak Likely To Spur Paranoia At High Court, Legal Pros Say
• WTO Releases Draft Of Controversial COVID Vaccine IP Waiver
• Dobbs Draft Could Jeopardize More Than Abortion Precedent
• 5th Circ. Told To Undo Block Of Texas Abortion Law
• IPO Lawyers See Mild Pickup In An Otherwise Cool Spring
• Week In Bankruptcy: Purdue On Defense, Becker Goes To Jail
• Biden Launches Mandatory Review Of Trump-Era China Tariffs
• Pharmacy Co. Investors Seek Final OK Of $15.5M Deal
• Amazon Pharmacy PillPack Pays $5.8M For Insulin Overbilling
• 1 Big Hurdle Blocks Senate Bid To Codify Abortion Rights
• 11th Circ. Asked To Revive Suit Over Opioid Claim Coverage
• Fox Rothschild Opens Boston Office With Mintz IP Team
• Pharma Co.'s Counsel Blasts Missed Deadlines In Del. Suit
• Leak Casts Pall On High Court Ahead Of Final Abortion Ruling
• Shook Hardy Adds Litigator To Lead New Hartford Office
• Ex-HHS Deputy GC Joins UpStream Healthcare In DC
• Wash. AG, Distributors Cut $518M Deal Ending Opioid Trial
• 5 Questions That Can Help Law Firms Win RFPs
• Have We Asked For Cannabis Legalization To Do Too Much?
• Drugmaker Loses Jurisdiction Challenge Over Royalties Suit
• Roberts Launches Probe Into Leaked Abortion Draft Opinion
• Court Says Pot Growers 'Fall So Short' In Calif. Cop RICO Suit
• ITC To Probe Drug Cos. Accused Of Using Medytox Secrets
• NHK-Fintiv Can't Be Challenged, Patent Office Tells Fed. Circ.
• Chinese Citizen Convicted Of Stealing GSK Trade Secrets
• IBF Properties Lands $150M Loan For 24 Walgreens Stores
• Juul And Altria Can't Cut Most Claims From Teen's Vaping Suit
• Catching Up With Delaware's Chancery Court
• How Law Firms Can Employ More Veterans
• Goodwin-Led Biotech Startup Launches Plans For $101M IPO
• Ex-Client Fights Buchanan Ingersoll's $1.9M Fee Lien